Kyverna Therapeutics to Report Topline Results from Registrational Phase 2 KYSA-8 Trial of KYV-101 in Stiff Person Syndrome
– Company to host live webcast and conference call Monday, December 15,…
Wave Life Sciences Prices Upsized $350 Million Public Offering of Ordinary Shares and Pre-Funded Warrants
December 09, 2025 21:50 ET Â | Source: Wave Life Sciences USA, Inc.…
Dyne Therapeutics Announces Pricing of Upsized $350.0 Million Public Offering of Common Stock
December 09, 2025 21:42 ET Â | Source: Dyne Therapeutics, Inc. WALTHAM, Mass.,…
Cerevance Showcases Positive Phase 2 Results Demonstrating Significant Reduction in OFF Time with Solengepras as an Adjunctive Treatment in Parkinsons Disease
December 05, 2025 21:00 ET Â | Source: Cerevance, Inc. Phase 2 results…
Genenta Reports Long-Term Survival Trends and Immune Findings in Brain Tumor (GBM) Trial
Company Announces Approximately $30 Million in Cash and Short-Term Investments Following Its…
Olema Oncology to Participate in 8th Annual Evercore Healthcare Conference
November 21, 2025 16:30 ET Â | Source: Olema Oncology SAN FRANCISCO, Nov.…
MAIA Biotechnology Highlights Ongoing Momentum of Ateganosine Clinical Program at SITC 2025
Company confirms 12 patients enrolled in Phase 2 THIO-101 to date as…
KX-826: Redefining Confidence with Visible Hair Revival
HongKong, Nov. 21, 2025 (GLOBE NEWSWIRE) -- For millions struggling with thinning…
Centessa Pharmaceuticals Announces Pricing of $250,000,000 Public Offering of American Depositary Shares
November 11, 2025 20:40 ET Â | Source: Centessa Pharmaceuticals plc BOSTON and…
BPGbio Appoints John Dvor as Executive Vice President, Corporate Development
BOSTON, Nov. 11, 2025 (GLOBE NEWSWIRE) -- BPGbio, Inc., a biology-first, AI-powered,…